RA0185

antibody from Oursmab
Targeting: DLL4
Provider product page for RA0185
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0185 - Provider product page
Provider
Oursmab
Product name
Demcizumab (Biosimilar Reference Antibody) (DLL4)
Antibody type
Monoclonal
Description
Demcizumab (also known as OMP-21M18) is an investigational humanized monoclonal antibody that was developed as a targeted therapy for solid tumors. It functions as an inhibitor of the Delta-like ligand 4 (DLL4) pathway, which is a key component of the Notch signaling system involved in tumor angiogenesis. By blocking DLL4, demcizumab aimed to disrupt the formation of functional tumor vasculature. It was evaluated in clinical trials, primarily in combination with chemotherapy, for the treatment of advanced cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer (NSCLC). Despite initial promise, its clinical development was discontinued after later-phase trials did not demonstrate a sufficient survival benefit to outweigh associated toxicities, including characteristic cardiovascular side effects linked to DLL4 inhibition.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
DLL4 protein structure - RA0185 shown in red.